Regional distribution of amyloid beta-protein precursor, growth-associated phosphoprotein-43 and microtubule-associated protein 2 messenger RNAs in the nigrostriatal system of normal and Weaver mutant mice and effects of ventral mesencephalic grafts.
Using in situ hybridization histochemistry with [32P]oligonucleotide probes, we studied the cellular localization of RNA transcripts for amyloid beta-protein precursor (beta APP), growth-associated phosphoprotein-43 (GAP-43) and microtubule-associated protein 2 (MAP2) in the mesostriatal system of normal (+/+) and weaver (wv/wv) mutant mice, which lose mesencephalic dopamine neurons. In addition, expression of the same messages was studied in ventral mesencephalic cell suspensions transplanted to the weaver striatum. Transcripts encoding GAP-43, MAP2 and isoforms beta APP695, beta APP714 and beta APP751 were present in normal substantia nigra and progressively reduced in weaver substantia nigra; such a reduction was correlated with dopamine neuron loss. The survival of dopamine neurons in unilateral intrastriatal grafts was documented by methamphetamine-induced rotational asymmetry tests and by tyrosine hydroxylase immunocytochemistry. High hybridization signals were obtained for GAP-43, MAP2, beta APP695, beta APP714 and beta APP751 RNA transcripts in the grafted tissue; the beta APP770 species--normally seen in striatum and not substantia nigra--was not expressed in the grafts, but it was present in the recipient striatum. Following immunocytochemical labelling with antibodies, GAP-43 and MAP2 immunoreactivities were seen in cell processes in the grafts and surrounding tissue, whereas beta APP immunoreactivity was mainly found in grafted cell bodies. These results suggest that the transplanted mesencephalic cells mature very similarly to those in the normal substantia nigra, expressing different mRNAs that are normally present in the ventral midbrain and which are reduced in the weaver mutant as a consequence of dopamine neuron loss.
Solà
C
C
Preclinical Research, Sandoz Pharma AG, Basel, Switzerland.
Mengod
G
G
Low
W C
WC
Norton
J
J
Ghetti
B
B
Palacios
J M
JM
Triarhou
L C
LC
D016564:Amyloid beta-Protein Precursor / Q000032:analysis / Q000096:biosynthesis*; D000818:Animals; D016380:Brain Tissue Transplantation / Q000502:physiology*; D003342:Corpus Striatum / Q000378:metabolism*; D005260:Female; D016332:Fetal Tissue Transplantation / Q000502:physiology; D019922:GAP-43 Protein; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis*; D008636:Mesencephalon / Q000378:metabolism* / Q000637:transplantation*; D051379:Mice; D008815:Mice, Inbred Strains / Q000378:metabolism; D008818:Mice, Neurologic Mutants / Q000378:metabolism*; D008869:Microtubule-Associated Proteins / Q000032:analysis / Q000096:biosynthesis*; D009419:Nerve Tissue Proteins / Q000032:analysis / Q000096:biosynthesis*; D010750:Phosphoproteins / Q000096:biosynthesis; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism*; D012016:Reference Values; D013378:Substantia Nigra / Q000378:metabolism*
D016564:Amyloid beta-Protein Precursor; D019922:GAP-43 Protein; D008562:Membrane Glycoproteins; D008869:Microtubule-Associated Proteins; D009419:Nerve Tissue Proteins; D010750:Phosphoproteins; D012333:RNA, Messenger